"Epigenetic" modification as therapy for acute myeloid leukemia
- PMID: 29211296
- PMCID: PMC6871512
- DOI: 10.1002/cncr.31137
"Epigenetic" modification as therapy for acute myeloid leukemia
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURES
Charles A. Schiffer reports participation in an advisory board for Celgene and participation in data safety and monitoring boards for Pfizer, Ambit, Astellas, Pharmacyclics, Takeda, and Juno outside the submitted work.
Comment on
-
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6. Cancer. 2018. PMID: 29211308 Free PMC article. Clinical Trial.
References
-
- Astex Pharmaceuticals. Guadecitabine (SGI-110). http://astx.com/research-development/clinical-pipeline/guadecitabine-sgi.... Accessed October 2017.
-
- Papaemmanuil E, Dohner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med 2016;375:900–901. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical